1 / 23

1 O’Connor OA et al. Proc ICML 2013;Abstract 138; Proc ASCO 2013;Abstract TPS8611.

slade
Download Presentation

1 O’Connor OA et al. Proc ICML 2013;Abstract 138; Proc ASCO 2013;Abstract TPS8611.

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. ECHELON-2: Phase 3 Trial of Brentuximab Vedotin and CHP versus CHOP in the Frontline Treatment of Patients (Pts) with CD30+ Mature T-Cell Lymphomas (MTCL)1Safety and Efficacy of Brentuximab Vedotin for Treatment of Relapsed or Refractory Mature T-/NK-Cell Lymphomas2Phase 3 Study of Brentuximab Vedotin versus Physician’s Choice of Methotrexate or Bexarotene in Patients (Pts) with CD30-Positive (CD30+) Cutaneous T-Cell Lymphoma. The ALCANZA Study3 1O’Connor OA et al.Proc ICML 2013;Abstract 138; ProcASCO 2013;Abstract TPS8611. 2Oki Y et al. Proc ICML 2013;Abstract 152. 3Kim YH et al. Proc ICML 2013;Abstract 572.

  2. ECHELON-2: Phase 3 Trial of Brentuximab Vedotin and CHP versus CHOP in the Frontline Treatment of Patients (Pts) with CD30+ Mature T-Cell Lymphomas (MTCL) O’Connor OA et al.Proc ICML 2013;Abstract 138;Proc ASCO 2013;Abstract TPS8611.

  3. Background • MTCLs, including systemic anaplastic large cell lymphoma (sALCL), are aggressive neoplasms. • Anthracycline-based multiagent chemotherapy regimens have demonstrated response rates ranging from 76% to 88% (JCO 2012;30(25):3093-9). • Brentuximab vedotin is an anti-CD30 monoclonal antibody conjugate that has demonstrated activity in a pivotal Phase II study as a single agent in relapsed/refractory sALCL (JCO 2012;30(18):2190-6). • In a Phase I study, it showed evidence of clinical activity when used in combination with CHP as front-line therapy for sALCL (Proc ASH 2012;Abstract 60). • Study objective: To evaluate the safety and efficacy of brentuximab vedotin with CHP versus CHOP as front-line therapy for patients with CD30-positive MTCL. O’Connor OA et al. Proc ICML 2013;Abstract 138; Proc ASCO 2013;Abstract TPS8611.

  4. Ongoing Phase III ECHELON-2 Trial Design (NCT01777152) 1:1 randomization Brentuximab/CHP Every 3 weeks 6–8 cycles R CHOP Every 3 weeks 6–8 cycles Study start date: January 2013 Estimated study completion date: December 2019 Brentuximab vedotin dose: 1.8 mg/kg (IV) • Primary endpoint: Progression-free survival (PFS) by independent review • Secondary endpoints include: PFS in sALCL by independent review, complete remission rate, overall survival, objective response rate, safety O’Connor OA et al. Proc ICML 2013;Abstract 138; Proc ASCO 2013;Abstract TPS8611.

  5. Study Methods • Patients will be stratified prior to randomization by: • ALK-positive sALCL versus other histologic subtypes • International prognostic index score (0-1, 2-3 or 4-5) • The target proportion of patients with a diagnosis of sALCL will be 75%. • After completion of treatment, all patients will be followed for disease progression, medical resource utilization, quality of life and survival. • Post-treatment stem cell transplant is allowed. O’Connor OA et al. Proc ICML 2013;Abstract 138; Proc ASCO 2013;Abstract TPS8611.

  6. Efficacy and Safety Assessments • Efficacy assessments will use the Revised Response Criteria for Malignant Lymphoma (JCO 2007;25(5):579). • CT and PET scans will be performed: • At baseline • After Cycle 4 • After completion of treatment • CT scans will also be performed at regular intervals during follow-up until disease progression, death or analysis of primary endpoint. • An independent data monitoring committee will review safety data on an ongoing basis. • Safety assessments will occur throughout the study until 30 days after last dose of study treatment. O’Connor OA et al. Proc ICML 2013;Abstract 138; Proc ASCO 2013;Abstract TPS8611.

  7. Assessment of Peripheral Neuropathy and Patient-Reported Outcomes • Peripheral neuropathy will be graded according to Common Terminology Criteria for Adverse Events and all dose modifications will be based on these grades. • In addition, Total Neuropathy Score — nurse (TNSn) will be used to assess the onset and resolution of peripheral neuropathy: • TNSn is designed to be used by trained medical professionals, not restricted to neurologists or physicians. • TNSn includes the measure of sensory, autonomic and motor symptoms; pin sensibility; and vibration sensibility. • Patient-reported outcomes will include questionnaires completed prior to the administration of treatment on study days: • Patient reports may be collected by phone upon disease progression and during survival follow-up. O’Connor OA et al. Proc ASCO 2013;Abstract TPS8611.

  8. Investigator Commentary: Ongoing ECHELON-2 Trial of Front-Line Brentuximab Vedotin/CHP versus CHOP in CD30-Positive MTCL The ECHELON-2 trial is a registration-directed study. I believe that the study is important because of the addition of brentuximab to CHP. Since it is only for CD30-positive MTCL, it will account for about a third of patients with T-cell lymphoma. At the moment, accrual is relatively slow as people get their arms around considering CD30 as part of their up-front diagnostic workup for patients with these diseases, but this trial could have a significant impact on the natural history of T-cell lymphoma. The early signals in patients with CD30-positive T-cell lymphoma and diffuse large B-cell lymphomasuggest that this agent is highly active in those patients. I believe that it may represent one of our first big advances to a CHP backbone by adding something new that could advance the up-front induction care of these patients. At the planning stage of the trial, the treatment schedule was a big discussion. The FDA judged that a fair comparison should include 6 to 8 cycles of CHOP chemotherapy versus 6 to 8 cycles of brentuximab vedotin/CHP. The trial includes no provision to administer an extended brentuximab vedotin regimen to patients who are randomly assigned to that treatment arm. Interview with Owen A O’Connor, MD, PhD, August 20, 2013

  9. Safety and Efficacy of Brentuximab Vedotin for Treatment of Relapsed or Refractory Mature T-/NK-Cell Lymphomas Oki Y et al. Proc ICML 2013;Abstract 152.

  10. Background • The MTCL subtypes angioimmunoblastic T-cell lymphoma (AITL) and PTCL not otherwise specified (PTCL-NOS) generally respond poorly to chemotherapy and often relapse (JCO 2013;31(16):1970). • Few effective treatment options are available and there is no standard therapy for relapsed/refractory MTCL. • CD30 is a target antigen variably expressed on several non-Hodgkin lymphoma cells, including B-cell lymphomas and MTCLs. • Brentuximab vedotin is an anti-CD30 monoclonal antibody conjugate. • Study objective: To assess the safety and efficacy of brentuximab vedotin in relapsed or refractory CD30-positive MTCL. Oki Y et al. Proc ICML 2013;Abstract 152.

  11. Phase II Trial Design Brentuximab vedotin 1.8 mg/kg (IV) every 3 weeks Restage at cycles 2, 4 and every 3 cycles thereafter *Enrollment to date • Diagnosis excludes anaplastic large-cell lymphoma (ALCL), Sézary syndrome and mycosis fungoides (MF) but includes: • AITL: n = 11 • PTCL-NOS: n = 18 • Primary endpoint: Objective response rate (ORR) • Secondary endpoints include: Correlation of CD30 expression with response, progression-free survival and safety Oki Y et al. Proc ICML 2013;Abstract 152.

  12. Maximal Tumor Volume Reduction 17 of 18 patients with postbaseline CT assessments With permission from Oki Y et al. Proc ICML 2013;Abstract 152.

  13. Maximal Tumor Volume Reduction by Frequency of CD30+ Cells Includes patients with both postbaselineradiographic response assessments and CD30 expression data With permission from Oki Y et al. Proc ICML 2013;Abstract 152.

  14. Best Clinical Response Median duration of response: Not yet reached Oki Y et al. Proc ICML 2013;Abstract 152.

  15. Adverse Events (AEs) Occurring in >10% of Patients • Grade 3 neutropenia (n = 3) • Grade 4 AEs to date include: Pulmonary edema, increased lipase and confused state (n = 1 each) Oki Y et al. Proc ICML 2013;Abstract 152.

  16. Author Conclusions • In this interim analysis, brentuximab vedotin demonstrated antitumor activity in patients with AITL • Objective response rate: 50% (CR = 40%; PR = 10%) • Median duration of response: not reached • Durable responses were observed in patients across a broad range of CD30 expression, including those with low or undetectable CD30 expression. • Brentuximab vedotin demonstrated antitumor activity in patients with relapsed/refractory MTCL and a safety profile consistent with labeled indications. Oki Y et al. Proc ICML 2013;Abstract 152.

  17. Investigator Commentary: Safety and Efficacy of Brentuximab Vedotin in Relapsed or Refractory Mature T-/NK-Cell Lymphomas This is a Phase II trial evaluating brentuximabvedotin for relapsed and refractory CD30-positive T-/NK-cell lymphomas that do not include ALCL. This setting is technically not an indication for brentuximabvedotin at the moment, but interest has arisen in evaluating this drug in different patient populations. Data were presented with a small number of patients from the trial so far, about 29 patients, and the authors specifically evaluated PTCL-NOS and angioimmunoblasticT-cell lymphoma (AITL). In the overall patient population the response rate was fairly high. It was about 36% for these patients. Among patients with AITL, about 50% of the patients responded, including 4 complete responses. Apparently this represents an interesting signal with which to move forward particularly in the population of patients with AITL. Interview with Julie M Vose, MD, MBA, July 19, 2013

  18. Phase 3 Study of Brentuximab Vedotin versus Physician’s Choice of Methotrexate or Bexarotene in Patients (Pts) with CD30-Positive (CD30+) Cutaneous T-Cell Lymphoma (CTCL). The ALCANZA Study Kim YH et al. Proc ICML 2013;Abstract 572.

  19. Background • A Phase II trial demonstrated clinical activity and a manageable safety profile with brentuximab vedotin in relapsed/refractory CD30+ mycosis fungoides (Proc ASH 2012;Abstract 797). • Overall response rate (ORR): 13/19 (68%) • Another Phase II trial demonstrated that brentuximab vedotin is an effective and safe targeted therapy for CD30+ CTCL and cutaneous lymphoproliferative disorders (Proc ASH 2012;Abstract 3688). • ORR: 63% (24/38) • The most common adverse events associated with brentuximabvedotin include peripheral neuropathyand fatigue. • Study objective: To evaluate the efficacy and safety of brentuximab vedotin versus physician’s choice in CD30+ CTCL. Kim YH et al. Proc ICML 2013;Abstract 572.

  20. Ongoing Phase III ALCANZA Trial Design (NCT01578499) Brentuximabvedotin1.8 mg/kg every 3 weeksfor up to 16 cycles R Physician’s choiceMethotrexate: 5-50 mg, q1wk or Bexarotene: 300 mg/m2qd Study start date: August 2012 Estimated study completion date: June 2015 MF = mycosis fungoides; pcALCL= primary cutaneous anaplastic large-cell lymphoma • Primary endpoint: ORR lasting ≥4 months • Secondary endpoints include: Complete response, progression-free survival and changes in burden of symptom domain per Skindex-29 questionnaire Kim YH et al. Proc ICML 2013;Abstract 572.

  21. Study Treatments • Patients will be stratified by diagnosis and randomly assigned to receive brentuximab vedotin or physician’s choice of methotrexate or bexarotene. • Patients who achieve a complete or partial response at cycle 3 may continue the study drug for up to 48 weeks. • Patients with stable disease and evidence of benefit may continue for a further 3 cycles. • Patients with increasing skin score (modified severity weighted assessment tool; mSWAT) prior to cycle 3 may continue until cycle 3 if it is due to tumor flare. Kim YH et al. Proc ICML 2013;Abstract 572.

  22. Efficacy and Safety Assessments • Response assessments will include: • Skin (mSWAT) • Nodal and visceral radiographic assessments • Detection of circulating Sézary cells (MF only) • ORR will be evaluated until disease progression or study closure. • Safety assessments will include: • Incidence and severity of adverse events • Changes to physical and laboratory tests • Enrollment into the ALCANZA trial is ongoing. Kim YH et al. Proc ICML 2013;Abstract 572.

  23. Investigator Commentary: The Phase III ALCANZA Trial of Brentuximab Vedotin versus Physician’s Choice in CD30+ CTCL This ongoing Phase III trial is comparing brentuximab to physician’s choice of either methotrexate or bexarotene for patients with CD30-positive cutaneous T-cell lymphoma. Most of these patients would be patients with mycosis fungoides, although other types of CTCL are represented. Prior to this trial studies have evaluated brentuximabvedotin for patients with CTCL, and data from a Phase II study were interesting. Anecdotally, I have used brentuximab for some patients with CTCL and they have had good responses, and I believe this will likely be an important setting to continue to investigate. Interview with Julie M Vose, MD, MBA, July 19, 2013

More Related